Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations

Míreanna Comhchosúla

• The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
  le: Xu, Jianlin, et al.
  Foilsithe: (2016)
• EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
  le: Xu, Jianlin, et al.
  Foilsithe: (2016)
• Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
  le: Xu, Jianlin, et al.
  Foilsithe: (2016)
• Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
  le: Lou, Yuqing, et al.
  Foilsithe: (2021)
• The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer
  le: Chen, Dongfang, et al.
  Foilsithe: (2019)